Idiosyncratic Drug-induced Liver Injury and the Role of Inflammatory Stress with an Emphasis on an Animal Model of Trovafloxacin Hepatotoxicity

Overview

Journal Toxicol Sci

Publisher Oxford University Press

Specialty Toxicology

Date 2010 Jun 12

PMID 20538741

Citations 45

Authors

Patrick J Shaw

Patricia E Ganey

Robert A Roth

Affiliations

Soon will be listed here.

Abstract

Idiosyncratic adverse drug reactions (IADRs) occur in a minority of patients yet account for the majority of postmarketing use restrictions by the Food and Drug Administration. Despite the impact of these toxicities, the underlying mechanisms are still poorly understood. Animal models of IADRs would be beneficial in understanding mechanisms and in developing assays with predictive potential. Recent work exploring the interactions between inflammatory stress and drugs associated with human idiosyncratic drug-induced liver injury (IDILI) has led to the development of the first animal models that apply to a range of drugs. Here, we discuss hypotheses for the mechanisms of IDILI and focus on a murine model of trovafloxacin-induced hepatotoxicity as an example related to the inflammatory stress hypothesis.

Citing Articles

Multi-epitope vaccine against drug-resistant strains of Mycobacterium tuberculosis: a proteome-wide subtraction and immunoinformatics approach.

Khan M, Mahmud A, Islam M, Sumaia M, Rahim Z, Islam K Genomics Inform. 2023; 21(3):e42.

PMID: 37813638 PMC: 10584640. DOI: 10.5808/gi.23021.

Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model.

Kaden T, Graf K, Rennert K, Li R, Mosig A, Raasch M Sci Rep. 2023; 13(1):13338.

PMID: 37587168 PMC: 10432496. DOI: 10.1038/s41598-023-40004-z.

Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans.

Ravindra K, Vaidya V, Wang Z, Federspiel J, Virgen-Slane R, Everley R Nat Commun. 2023; 14(1):1215.

PMID: 36869085 PMC: 9984368. DOI: 10.1038/s41467-023-36858-6.

Pharmacology of pannexin channels.

Koval M, Schug W, Isakson B Curr Opin Pharmacol. 2023; 69:102359.

PMID: 36858833 PMC: 10023479. DOI: 10.1016/j.coph.2023.102359.

Acetaminophen-Induced Hepatotoxicity in Obesity and Nonalcoholic Fatty Liver Disease: A Critical Review.

Begriche K, Penhoat C, Bernabeu-Gentey P, Massart J, Fromenty B Livers. 2023; 3(1):33-53.

PMID: 36713231 PMC: 9879315. DOI: 10.3390/livers3010003.

References

Sanne I, Mommeja-Marin H, Hinkle J, Bartlett J, Lederman M, Maartens G . Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005; 191(6):825-9. DOI: 10.1086/428093. View

Pirmohamed M, James S, Meakin S, Green C, Scott A, Walley T . Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329(7456):15-9. PMC: 443443. DOI: 10.1136/bmj.329.7456.15. View

Bemelmans M, van Tits L, Buurman W . Tumor necrosis factor: function, release and clearance. Crit Rev Immunol. 1996; 16(1):1-11. DOI: 10.1615/critrevimmunol.v16.i1.10. View

Cheng L, You Q, Yin H, Holt M, Franklin C, Ju C . Effect of polyI:C cotreatment on halothane-induced liver injury in mice. Hepatology. 2008; 49(1):215-26. PMC: 2636554. DOI: 10.1002/hep.22585. View

Waring J, Anderson M . Idiosyncratic toxicity: mechanistic insights gained from analysis of prior compounds. Curr Opin Drug Discov Devel. 2005; 8(1):59-65. View

He K, Talaat R, Pool W, Reily M, Reed J, Bridges A . Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab Dispos. 2004; 32(6):639-46. DOI: 10.1124/dmd.32.6.639. View

Gurumurthy P, Krishnamurthy M, NAZARETH O, Parthasarathy R, Sarma G, SOMASUNDARAM P . Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis. 1984; 129(1):58-61. DOI: 10.1164/arrd.1984.129.1.58. View

Huang Y . Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol. 2007; 3(1):1-8. DOI: 10.1517/17425255.3.1.1. View

Keller B, Yamanaka H, Thurman R . Inhibition of mitochondrial respiration and oxygen-dependent hepatotoxicity by six structurally dissimilar peroxisomal proliferating agents. Toxicology. 1992; 71(1-2):49-61. DOI: 10.1016/0300-483x(92)90053-h. View

10.

Li A . A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact. 2002; 142(1-2):7-23. DOI: 10.1016/s0009-2797(02)00051-0. View

11.

Lee W . Drug-induced hepatotoxicity. N Engl J Med. 2003; 349(5):474-85. DOI: 10.1056/NEJMra021844. View

12.

Lasser K, Allen P, Woolhandler S, Himmelstein D, Wolfe S, Bor D . Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002; 287(17):2215-20. DOI: 10.1001/jama.287.17.2215. View

13.

Boelsterli U, Lim P . Mitochondrial abnormalities--a link to idiosyncratic drug hepatotoxicity?. Toxicol Appl Pharmacol. 2007; 220(1):92-107. DOI: 10.1016/j.taap.2006.12.013. View

14.

Wilke R, Lin D, Roden D, Watkins P, Flockhart D, Zineh I . Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov. 2007; 6(11):904-16. PMC: 2763923. DOI: 10.1038/nrd2423. View

15.

Shaw P, Fullerton A, Scott M, Ganey P, Roth R . The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability. Toxicol Appl Pharmacol. 2009; 236(3):293-300. DOI: 10.1016/j.taap.2009.01.018. View

16.

Aithal G, Ramsay L, Daly A, Sonchit N, Leathart J, Alexander G . Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology. 2004; 39(5):1430-40. DOI: 10.1002/hep.20205. View

17.

Schwab C, Tuschl H . In vitro studies on the toxicity of isoniazid in different cell lines. Hum Exp Toxicol. 2003; 22(11):607-15. DOI: 10.1191/0960327103ht401oa. View

18.

Park B, Coleman J, Kitteringham N . Drug disposition and drug hypersensitivity. Biochem Pharmacol. 1987; 36(5):581-90. View

19.

Waring J, Liguori M, Luyendyk J, Maddox J, Ganey P, Stachlewitz R . Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther. 2005; 316(3):1080-7. DOI: 10.1124/jpet.105.096347. View

20.

Murphy E, Davern T, Shakil A, Shick L, Masharani U, Chow H . Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. Dig Dis Sci. 2000; 45(3):549-53. DOI: 10.1023/a:1005405526283. View